T
Tetsuya Mitsudomi
Researcher at Kindai University
Publications - 583
Citations - 51959
Tetsuya Mitsudomi is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 97, co-authored 541 publications receiving 46183 citations. Previous affiliations of Tetsuya Mitsudomi include University of Occupational and Environmental Health Japan & Gunma University.
Papers
More filters
Journal ArticleDOI
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].
Shengxiang Ren,J. Wang,Jianming Yang,Tetsuya Mitsudomi,D.H. Lee,Z. Wang,Qian Chu,Philip C. Mack,Y. Cheng,Jipeng Duan,Y. Fan,Baohui Han,Zhouguang Hui,A Liu,J Liu,Y. Lu,Z. Ma,M. Shi,Yongqian Shu,Q. Q. Song,X. Song,C. Wang,X. Wang,Z. Wang,Y. Xu,L. Zhang,M. Zhao,Biyun Zhu,J. Zhang,C. Zhu,Fred R. Hirsch +30 more
TL;DR: Ying et al. as discussed by the authors proposed a consensus for HER2 alterations testing in non-small-cell lung cancer and found that such alterations are, in general, considered markers of poor prognosis.
clinical significance Expression of human telomerase subunit genes in primary lung cancer and its
Takashi Takahashi,Tetsuya Mitsudomi,Mitsuyuki Arinaga,Shigeki Shimizu,Kunihiko Gotoh,Nobuhiro Haruki +5 more
Journal ArticleDOI
Propensity score analysis for the efficacy of preoperative antibiotics in patients with resected primary lung cancer: Levofloxacin versus cefazolin
Kenji Tomizawa,Junichi Soh,Hana Oiki,Shota Fukuda,Masaya Nishino,Katsuaki Sato,Tetsuya Mitsudomi +6 more
Patent
Procédé et composition pour prédire la récurrence postchirurgicale chez un patient atteint d'un adénocarcinome pulmonaire
TL;DR: In this paper, a procede for predire the recurrence of adenocarcinome pulmonaires apres l'elimination chirurgicale du cancer du poumon chez un patient atteint d'un adnocarcine pulmonaire en utilisant un jeu de genes specifiques.
Journal ArticleDOI
Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
Marco H. Hofmann,Sabine Jurado,Daniel Gerlach,Takamasa Koga,Francesca Trapani,Michael Gmachl,Donát Alpár,Simone Lieb,Astrid Jeschko,Tetsuya Mitsudomi,Norbert Kraut,Mark Petronczki +11 more
TL;DR: Hofmann et al. as discussed by the authors used different preclinical experimental approaches to interrogate KRASG12C inhibitor resistance mechanisms with the aim to identify strategies to overcome resistance, and showed that the pan-KRAS SOS1 inhibitor BI 1701963 is the first direct RAS signaling modifier in phase I clinical trials both as a monotherapy as well as in combination with KRASg12C inhibitors, MEK inhibitors and liposomal irinotecan.